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Background: One of the critical tasks in analytical testing is to monitor and assign the infectivity or potency of
viral based vaccines from process development to production of final clinical lots. In this study, a high throughput
RT-qPCR based approach was developed to evaluate the infectious titre in a replication-defective HSV-2 candidate
vaccine, called HSV529. This assay is a combination of viral propagation and quantitative RT-PCR which measures
the amount of RNA in infected cells after incubation with test samples.
Results: The relative infectious titre of HSV529 candidate vaccine was determined by a RT-qPCR method
targeting HSV-2 gD2 gene. The data were analyzed using the parallel-line analysis as described in the European
Pharmacopoeia 8th edition. The stability of HSV529 test samples were also investigated in a concordance study
between RT-qPCR infectivity assay and a classical plaque assays. A suitable correlation was determined between
both assays using an identical sample set in both assays. The RT-qPCR infectivity assay was further characterized
by evaluating the intermediate precision and accuracy. The coefficient of variation from the six independent assays
was less than 10%. The accuracy of each of the assay was also evaluated in the range of 92.91% to 120.57%.
Conclusions: Our data demonstrate that the developed RT-qPCR infectivity assay is a rapid high throughput
approach to quantify the infectious titer or potency of live attenuated or defective viral-based vaccines, an attribute
which is associated with product quality.
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The conventional in-vitro assays to measure the titer or
potency of live viral-based vaccines are usually based on
the infectivity of the vaccine virus in cell cultures
(plaque assay or CCID50) [1-5]. In both methods, the
experiment duration is long due to the time needed for
virus replication producing the biological effect. In
addition, there is a cell substrate limitation with the
traditional methods, and only viruses that cause a
detectable biological effect on infected cells can be
evaluated.
The introduction of real time PCR technology for
the quantitation of viral infectivity has significantly
improved viral infectivity assays. This method is a* Correspondence: ali.azizi@sanofipasteur.com
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reproduction in any medium, provided the orcombination of virus propagation and quantitative PCR
(qPCR) or RT-qPCR. In a study by Ranheim et al., [6] a
RT-qPCR assay was developed to detect rotavirus vac-
cine (Rota Teq) infectivity within two days. In this assay,
the confluent Vero cells in 96-well plates were inocu-
lated with serial dilutions of test samples, a pentavalent
reassortant rotavirus reference standard, and assay
controls. After 24 hours, Vero cells were lysed and the
lysates were measured by RT-qPCR to quantify viral rep-
lication. In another study, Schalk et al., [4] developed a
rapid assay for the measurement of infectivity-potency
in MMR trivalent vaccines based on a qPCR infectivity
assay. The assay was able to demonstrate the potency of
mumps and measles viruses within a period of 2 days.
Since rubella virus replicates slower than measles and
mumps, the potency estimation for rubella virus was
PCR-based assays as end-points since a plaque assay for
measles and rubella virus usually takes 9 days [4]. Thisd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is 6 days. A one week time reduction in the qPCR infect-
ivity assay without loss of precision compared to a plaque
assay and TCID50 was a major advantage of the assay.
Dr. Knipe’s group at Harvard Medical School con-
structed a candidate Herpes Virus vaccine through dele-
tion of the UL5 and UL29 coding regions of HSV-2
virus [7]. The resultant vaccine, HSV529, is being devel-
oped by Sanofi Pasteur and is currently under a human
phase I clinical trial [8,9]. The AV529-19 cell line is used
for the propagation of HSV529. This cell line is a Vero-
based cell line specifically engineered to express the
HSV-1 UL5 and UL29 transgenes. With expression of
the HSV-1 UL5 and UL29 genes, AV529-19 is able to
support replication of HSV529 [8,9]. Herein, we have de-
veloped a high throughput RT-qPCR-based approach for
evaluation of the infectious titer of HSV529 candidate
vaccine. The developed infectivity RT-qPCR based ap-
proach determines relative quantification to an appropri-
ately constructed in-house reference control. The assay’s
accuracy and intermediate precision was also investi-
gated to ensure suitable performance of this analytical
method. Furthermore, a concordance stability study be-
tween the developed method and a classical plaque assay
was performed to investigate the correlation between
both assays. The results obtained from both assays using
the same identical sample set demonstrated a suitable linear
correlation between both approaches. In summary, the
developed RT-qPCR infectivity assay is a rapid method
with high-throughput capacity that can be applied to
quantify the infectious titer of HSV529 candidate vac-
cine. This approach could also be applied to other live
or attenuated viral vaccines to quantify the infectious
titer of product.
Results
Specificity of HSV-2 various target genes and
optimization of harvest time
The accumulation of HSV529 RNA during infection was
measured by one step RT-qPCR at 3, 6, 12, 16, and
24 hours post-infection using specific primers for ICP27,
TK, and gD2. A sufficient quantity of RNA from cells in-
fected with HSV529 was extracted by adding 50 μl of
each HSV529 dilution to each well in a 96-well plate for-
mat. The cells were lysed, RNA was purified, DNase
treated, and one-step RT-qPCR was performed. After
RT-qPCR, CT values of each targeted gene were plotted
versus time post infection. No trends were observed for
plots of CT versus HSV529 concentration for studies tar-
geting ICP27 or TK genes 3–24 hours post-infection
(Figure 1B and 1C). However, one-step RT-qPCR using
gD2 primers showed a linear relationship between the
logarithm of the viral concentration and the CT values
12–16 hr post-infection. The slope of the graph flattens,and no trends were observed 24 hours post-infection as
replication of HSV529 virus, causes death of AV529-19
cells over time. The accumulation of HSV529 viral con-
centration during infection at 3, 6, 12, 16, and 24 hours
post-infection using specific gD2 primers is shown in
Figure 1A. The overall results show that HSV-2 gD2 is a
suitable targeted gene for evaluation of HSV529 infec-
tious titre 12–16 hour post-infection.
Evaluate the infectivity of HSV529 test samples by
targeting HSV-2 gD2 gene
The assay targeting gD2 was performed six times in a
96-well plate format and the results were analyzed
through extrapolation or PLA software 2.0. Briefly,
96-well plates were seeded with AV529-19 a day before
infection. Next day, cells were infected with the serial di-
lutions of HSV529 (5 dilutions with 4 replicates for each
dilution). The same lot of HSV529 was used as both test
sample and in-house reference control in all six inde-
pendent assays. RNA was extracted 16 hours post infec-
tion, treated with DNase, RT-qPCR performed targeting
HSV-2 gD2, and infectious titer assigned by PLA ana-
lysis. Since the same HSV529 lot was used as the test
sample and the in-house reference control, it was ex-
pected to observe two close parallel lines (infectious titer
ratio of ~1.0) after PLA analysis. The infectious titer ra-
tio, 95% confidence interval, and relative confidence
interval observed for the six independent assays are
shown in Figure 2. A simplified diagram from the devel-
oped RT-qPCR infectivity assay targeting HSV-2 gD2
gene is shown in Figure 3.
A comparative stability study between RT-qPCR infectivity
assay and a classical plaque assay
To determine if RT-qPCR infectivity assay is a suitable
approach to evaluate the stability of HSV529 test sam-
ples, a concordance study between the RT-qPCR infect-
ivity assay and a plaque assay was conducted using
identical test samples set in both assays. HSV529 test
samples were incubated at 4–8°C or 22–25°C in various
time points and the infectious titre was measured by a
classical plaque assay. These samples set were also tested
by the RT-qPCR infectivity assay and the results were
analyzed by extrapolation or PLA. A suitable correlation
was observed between PLA or extrapolation analysis
(Figure 4). A suitable correlation was also determined
between the infectious titer as measured by RT-qPCR in-
fectivity assay or plaque assay (Table 1).
Evaluation of intermediate precision and accuracy in the
developed RT-qPCR infectivity assay
To evaluate the intra-laboratory variation and closeness
of data, the intermediate precision and accuracy of the
developed RT-qPCR infectivity assay was assessed. For
Figure 1 The accumulation of HSV529 RNA after post-infection. The infected cells were lysed after each time point (3, 6, 12, 16, and
24 hours post-infection), RNA was purified followed by DNase treatment, and RT-qPCR performed using specific primers for HSV-2. A. The
accumulation of HSV529 targeting gD2 gene is shown. A linear relationship between the logarithm of the HSV529 concentration and the CT
values were observed at 12 to 16 h post-infection. B. The accumulation of HSV529 targeting ICP-27 gene is shown No linear relationship between
the logarithm of the HSV529 concentration and the CT values were observed at any time points (3, 6, 12, 16, and 24 h). As a representative, the
accumulation of HSV529 RNA targeting ICP-27 after 6 h and 12 h post-infection is shown. C. The accumulation of HSV529 RNA targeting TK gene
after 3 h and 6 h post-infection is shown. No linear relationship between the logarithm of the HSV529 concentration and the CT values were
observed at any time points (3, 6, 12, 16, and 24 h). dil:dilution.
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was used as both test sample and in-house reference
control. As described, AV529-19 cells were infected and
the total RNA was extracted and processed 16 hours
post-infection. RT-qPCR was performed targeting gD2
gene, and the results were analyzed through PLA soft-
ware version 2.0. The assay was performed six times by
two analysts on different days over a period of two
months. The coefficient of variation (%CV) from the six
independent assays was 9.19%. The accuracy of the assay
was calculated by evaluating the percentages of values
obtained by RT-qPCR infectivity assay versus the ex-
pected infectious titre values by plaque assay (1.41 × 107
pfu/ml). The accuracy of assay was evaluated in the
range of 92.91% to 120.57% (Table 2).
Discussion
There are several challenges with conventional in-vitro
assays (plaque or CPE) to measure the titer of live
attenuated or defective viral-based vaccines [4,6]. Thetraditional assays are usually laborious and sometimes
hard to interpret. The time due to-assay-completion and
cell substrate limitations are also challenges with the
conventional in-vitro assays. For instance, it takes nine
days to measure the infectious titre in measles or rubella
vaccines [4]. Furthermore, traditional methods require
virus neutralization for characterization of infectivity or
potentially potency in multivalent viral vaccines. How-
ever, a PCR-infectivity based approach does not require
virus neutralization, making it a more attractive alterna-
tive for multivalent viral vaccines. Although HSV529
candidate vaccine has not been faced with some of these
challenges (the HSV-2 virus is able to form plaques in
AV529-19 cells over 3 days and is not a multivalent vac-
cine), a RT-qPCR infectivity based-approach was devel-
oped to enhance the assay’s throughput (testing more
samples in a shorter time).
During HSV-2 replication, the five viral genes expressed
in the immediate-early (phase α), encode regulatory pro-
teins [10,11]. After the immediate-early step, early genes
Figure 2 The infectious titer ratios from six independent assays using the same lot of HSV529 as the in-house reference control and
the test sample. A. PLA analysis and acceptance criteria from one representative assay. B. The infectious titer ratio, 95% confidence interval,
and relative confidence interval observed for the six independent assays are shown.
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for replication of the viral genome. After genome replica-
tion in the early phase, the late step (phase γ) occurs,
where HSV-2 structural proteins are expressed and the
virus is formed [10,11]. One of the critical features of the
RT-qPCR infectivity assay was to determine the specificity
of the assay targeting appropriate HSV-2 gene. Therefore,
one gene (ICP27, TK, and gD2) from each of the replica-
tion phases was targeted. We were able to observe a linear
relationship between the logarithm of the HSV529 con-
centration and the CT values by targeting the gD2 gene
and not the ICP27 or TK genes. It has to be noted that
during the late gD2 expression, the immediate-early and
early proteins are also generated and the full form of the
virus is completed. HSV-2 gD2 RNA accumulation startsFigure 3 Overview of the developed RT-qPCR infectivity assay. Ninety
infected with the serial dilutions of HSV529 or in-house reference control. R
RT-qPCR performed targeting HSV-2 gD2, and infectious titer assigned by Pto level off approximately 12 hours post-infection and re-
mains relatively steady for up to 16 hour post-infection.
The developed assay is a combination of in-vitro
HSV529 propagation in the suitable cell line for a short
HSV-2 replication cycle followed by a RT-qPCR. The in-
fectious titers of the test samples are estimated relative
to an in-house reference control. This in-house refer-
ence control was titrated in the lab using conventional
plaque assay and validated based on 30 independent
assays accordance to the International Conference on
Harmonisation (ICH) guideline [12]. Therefore, the assay
measures the relative infectious unit based on the
in-house reference control unitage. Briefly, confluent
AV529 cells in 96-well plates were inoculated with serial
dilutions of HSV529 test samples and an HSV529 in-six well plates were pre-seeded with AV529-19. Next day, cells were
NA was extracted 16 hours post infection, treated with DNase,
LA analysis.
Figure 4 Correlation between the results analyzed by extrapolation or PLA. The infectious titer was evaluated by RT-qPCR and the results
were analyzed by both extrapolation and PLA.
Table 1 Infectious titre results obtained by RT-qPCR
infectivity assay or plaque assay
A.
0-1 hr 1 day 3 days 6 days 7 days
RT-qPCR
infectivity
7.50E + 06 7.28E + 06 4.35E + 06 3.35E + 06 2.43E + 06
Plaque
assay




3.06E + 06 1.14E + 06 2.14E + 06 1.30E + 06 3.78E + 05
Plaque
assay
3.23E + 06 3.40E + 06 2.80E + 06 1.55E + 06 N/A
HSV529 test samples were incubated at A. 4–8°C or B. 22-25°C at various time
points and the infectious titre was measured by RT-qPCR infectivity assay or
plaque assay.
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incubation for 16 hours. Thereafter, HSV529-19 cells
were lysed, total RNA purified, DNAse treated, and
RT-qPCR targeting HSV-2 gD2 gene was performed to
quantitate HSV529 nucleic acid produced during repli-
cation. The relative infectious titre for each sample was
determined using the parallel-line analysis as described
in the European Pharmacopoeia 8.0 [13]. The analysis by
extrapolation is not an appropriate approach as several
parameters including the similar conditions between the
in-house reference control and test samples are not con-
sidered during analysis. In this study, the correlation be-
tween test samples and the in-house reference control
was assessed using PLA software version 2.0. Before
PLA analysis, all CT values for the in-house reference
control and test samples were subjected to standard out-
lier analysis, with the limit that no more than one data
point (one replicate out of the four replicates) per
HSV529 dilution could be removed. Afterwards, each
assay was analyzed by PLA software. The assay was con-
sidered valid if the regression, linearity, and parallelism
were significant.
To investigate if RT-qPCR infectivity assay is a suitable
method to evaluate the stability of HSV529 test samples,
a concordance study was conducted between the RT-
qPCR infectivity assay and a conventional infectivity
plaque assay using identical test samples. While the re-
sults illustrated a suitable correlation (R2 ~0.91) between
the qRT-PCR infectivity assay and the plaque assay,
higher cost and complexity of RT-qPCR infectivity assay
were two drawbacks of this method compare to a trad-
itional method.
To evaluate the closeness of the analytically deter-
mined HSV529 infectious titre values, the accuracy of
the method was evaluated in six independent assays
by two analysts on different days. The accuracy wasdetermined as the percentage of the infectious titre
values obtained by RT-qPCR versus infectious titre
values by a plaque assay. The accuracy was evaluated in
the range of 92.91% to 120.57%, indicating a suitable ac-
curacy for the assay. The intermediate precision of the
assay was also evaluated to measure the variation of the
obtained data. To evaluate this parameter, the assay was
performed six times by two different operators over a
time period of 2 months. The mean value of this run
control was 16.53 log pfu/ml with a standard deviation
of 0.091, resulting in a coefficient of variation of 9.19.
Conclusions
In this study, a RT-qPCR based approach was utilized to
specifically detect and quantitate the HSV529 RNA after
productive infection in AV529-19 cells. The results show
that the developed RT-qPCR infectivity assay is a repro-
ducible approach that can quantitate the HSV529
infectious titre before the plaque assay formation is
visible on day 3. The described RT-qPCR infectivity





Plaque assay Accuracy% CV%
(Mean from 30 assays)
1 1.50E + 07 16.52 1.41E + 07 106.38
2 1.63E + 07 16.60 115.60
3 1.45E + 07 16.48 102.34
4 1.70E + 07 16.64 120.57
5 1.54E + 07 16.54 109.22
6 1.31E + 07 16.38 92.91 9.19
RT-qPCR infectivity assay was performed six times by two analysts on different days. The accuracy of the assay was calculated by evaluating the percentages of
values obtained by RT-qPCR infectivity assay versus the expected infectious titre values by plaque assay. The CV% from the six independent assays is
also determined.
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The infectious titre of an HSV529 (lot#10954) was deter-
mined through a plaque assay on AV529 cells by per-
forming 30 independent plaque assays. This lot was
determined as the HSV529 in-house reference control.
Briefly, serial dilutions of the viral material was allowed
to adsorb on the AV529 cell monolayers at 36°C ± 1°C,
5% ± 2% after which the volume of infection media was
adjusted to a suitable volume to allow for incubation at
36°C ± 1°C, 5% ± 2% for 48 hours. After the 48 hour in-
cubation step, the cell monolayers were fixed and
stained with a crystal violet (Sigma) and methanol stain
and the visible plaques were enumerated by eye and
used to assign a titre in log10 pfu/ml. The assigned
mean infectious titre from 30 independent assays was
1.41 × 107 pfu/ml.
Cell culture and infection
AV529-19 cells were cultured in DMEM/F12 (Sigma)
supplemented with 1% (v/v) Penicillin/Streptomycin
(Sigma), 1% heat inactivated ultra-low IgG-FBS (Invitro-
gen), 1% L-glutamine (Sigma), and maintained in a 37°C
incubator in 5% CO2. Prior to each assay, cells were
plated one day in advance in 96-well tissue culture plates
(Becton Dickinson) at a density of 4×104 cells per well
in a volume of 200 μl. Next day, plates were visually
inspected under a microscope to confirm the cell mono-
layer was 80-100% confluent. Serial dilutions of the
HSV529 test samples as well as the HSV529 in-house
reference control were prepared in culture media. The
media from each well was removed, and 50 μl of each
viral dilution was added to each well (four replicates
were used for each dilution). Afterwards, 50 μl media
was dispensed into each infected well for a totalvolume of 100 μl. Afterwards, 100 μl media was
added to the uninfected and negative control wells.
The plates were placed at 36 ± 1°C, 5% CO2 incubator
for 16 hours.
RNA isolation
Total RNA was isolated using total RNA purification
96-well kit (Norgen Biotek). The purified RNA was
treated with TURBO DNA-free kit (Applied Biosystems)
according to manufacture’s instruction.
Quantitative real-time RT-PCR (RT-qPCR)
The RT-qPCR was performed by targeting the HSV-2 im-
mediate early (ICP27), early (TK) and late (gD2) genes.
For ICP27, the forward and reverse primers were 5′- GCC
ACT CTC TTC CGA CAC -3′ and 5′- CAA GAA CAT
CAC ACG GAA C-3′, respectively. For TK, the forward
and reverse primers were 5′-TGG ATT ACG ATC AGT
CGC C -3′ and 5′-ACA CCA CAC GAC AAC AAT GC-
3′, respectively. For gD2, the forward and reverse primers
were 5′-TCA GCG AGG ATA ACC TGG GA-3 and
5′-GGG AGA GCG TAC TTG CAG GA-3, respectively.
The ICP27, TK, and gD2 primers have been previously
described and tested in other studies. [14-16]. All the
primers were purchased from Life Biotechnologies. One
step RT-qPCR was performed using SYBR Green PCR
master mix (Applied Biosystems), MultiScribe Reverse
Transcriptase (50 U/μl, Applied Biosystems), RNase
Inhibitor (20 U/μl, Applied Biosystems), 1 pmol of each
forward and reverse primer, and 2 μl isolated RNA in a
total volume of 25 μl. The RT-qPCR program consisted of
30 min reverse transcription reaction at 48°C, 10 min de-
naturation at 95°C, 40 cycles of 15 seconds denaturation
at 95°C, 1 min annealing at 60°C and extension at 95°C for
15 seconds. The assay was performed using the Mastercy-
cler® ep realplex (Eppendorf).
Data analysis
The data from the qRT-PCR infectivity assay were
analyzed by the extrapolation statistical approach using
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or Parallel-Line Analysis (PLA) using the PLA software
version 2.0.
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